Equibles does not estimate personal net worth.
Get an email with a short summary when Axsome Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get AXSM alertsMark Jacobson is recorded as COO at Axsome Therapeutics, Inc. (AXSM). The newest filing on record that lists Mark Jacobson as COO at Axsome Therapeutics, Inc. (AXSM) is dated April 24, 2026. The proxy statement of Axsome Therapeutics, Inc. reports total compensation of $4,208,131 for Mark Jacobson in fiscal 2025, including a base salary of $575,000. Disclosed compensation is on record for 7 fiscal years. Mark Jacobson has spoken on 21 earnings calls and 10 other investor events across 1 company, most recently for Axsome Therapeutics, Inc. on September 16, 2026. Axsome Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Axsome Therapeutics, Inc. includes Herriot Tabuteau (CEO), Nick Pizzie (CFO), Hunter Murdock (General Counsel) and 3 others.
“I'd say probably the one thing you won't necessarily substitute is that face-to-face interaction with the HCP. There is, you know, that's something that the doctors truly value is understanding the product directly from an Axlom or an Axlom representative.”
“I'd say probably the one thing you won't necessarily substitute is that face-to-face interaction with the HCP. There is, you know, that's something that the doctors truly value is understanding the product directly from an Axlom or an Axlom representative.”
“But, you know, Axome, CNS-focused, Biopharma, we have three products that are commercial products. Those are Ovelity for major depressive disorder and agitation associated with Alzheimer's disease.”
“And, you know, thanks for having us, Richard. It's really good to be here, and it's so far a really, really productive day for us. So I appreciate the opportunity to chat with you.”
“And, you know, thanks for having us, Richard. It's really good to be here, and it's so far a really, really productive day for us. So I appreciate the opportunity to chat with you.”
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
COO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Axsome Therapeutics, Inc. (AXSM) | M.A. Chief Operating Officer | $575,000 | $4,208,131 |
| 2024 | Axsome Therapeutics, Inc. (AXSM) | M.A. Chief Operating Officer | $552,000 | $4,245,813 |
| 2023 | Axsome Therapeutics, Inc. (AXSM) | M.A. Chief Operating Officer | $530,000 | $4,036,250 |
| 2022 | Axsome Therapeutics, Inc. (AXSM) | M.A. Chief Operating Officer | $483,000 | $3,785,242 |
| 2021 | Axsome Therapeutics, Inc. (AXSM) | M.A. Chief Operating Officer | $409,000 | $4,794,824 |
| 2020 | Axsome Therapeutics, Inc. (AXSM) | M.A. Chief Operating Officer | $375,000 | $2,365,005 |
| 2019 | Axsome Therapeutics, Inc. (AXSM) | M.A. Chief Operating Officer | $310,000 | $1,955,681 |
